Open AccessTelaprevir Activity in Treatment-Naive Patients Infected Hepatitis C Virus Genotype 4: A Randomized Trial
Author(s) -
Y. Benhamou,
J. Moussalli,
Vlad Ratziu,
Pascal Lebray,
Katie Backer,
Sandra De Meyer,
A Ghys,
Donghan Luo,
Gastón Picchio,
Maria Beumont
Publication year - 2013
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jit274
Subject(s) - telaprevir , medicine , adverse effect , ribavirin , gastroenterology , discontinuation , pegylated interferon , hepatitis c virus , placebo , virology , virus , pathology , alternative medicine
This partially blinded, randomized, phase 2a C210 study evaluated the antiviral activity of telaprevir-based regimens in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 4 infection.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom